Copy to clipboard 
Royal Biologics commenced U.S. commercial launch of BIOINCYTE PRFM, a next-generation Platelet Rich Plasma (PRP) system. BIOINCYTE converts traditional PRP to Platelet Rich Fibrin Matrix (PRFM) formulations. BIOINCYTE is designed to eliminate extensive contamination of red blood cells and white blood cells during the formulation of PRP.
BIOINCYTE removes virtually all contaminating cells, creating an ultra-pure PRFM. PRP is converted to PRFM through a controlled process, creating a scaffold that serves to protect and preserve platelets. By creating a fibrin matrix scaffold for the activated platelets, BIOINCYTE has been designed to create a longer-lasting bio-active environment for platelets to release growth factors. The BIOINCYTE bioactive scaffold is utilized within a controlled environment and sustains platelet growth factor releases over a course of days.
Platelet Rich Fibrin Matrices demonstrate many advantages over traditional PRP. PRFM has the ability to retain more growth factors than you would typically see in normal PRP devices. PRFM provides a softer more insulated approach to platelet separation, which allows for less trauma to individual blood cells. The PRFM scaffold matrix allows users to deliver more beneficial cells to the treatment site. Platelets and growth factors remain viable in a bio-active scaffolding environment with a controlled time release lasting for days, as opposed to traditional PRP which generally has a controlled time release only lasting for minutes to hours.
“The BIOINCYTE Platelet Rich Fibrin Matrix System creates a unique scaffold to localize platelets to the site of injection which allows for sustained growth factor release, migration of stem cells and reservoir for regenerative signaling,” said Salvatore Leo, Chief Executive Officer of Royal Biologics.
Source: Royal Biologics
Royal Biologics commenced U.S. commercial launch of BIOINCYTE PRFM, a next-generation Platelet Rich Plasma (PRP) system. BIOINCYTE converts traditional PRP to Platelet Rich Fibrin Matrix (PRFM) formulations. BIOINCYTE is designed to eliminate extensive contamination of red blood cells and white blood cells during the formulation of PRP.
...
Royal Biologics commenced U.S. commercial launch of BIOINCYTE PRFM, a next-generation Platelet Rich Plasma (PRP) system. BIOINCYTE converts traditional PRP to Platelet Rich Fibrin Matrix (PRFM) formulations. BIOINCYTE is designed to eliminate extensive contamination of red blood cells and white blood cells during the formulation of PRP.
BIOINCYTE removes virtually all contaminating cells, creating an ultra-pure PRFM. PRP is converted to PRFM through a controlled process, creating a scaffold that serves to protect and preserve platelets. By creating a fibrin matrix scaffold for the activated platelets, BIOINCYTE has been designed to create a longer-lasting bio-active environment for platelets to release growth factors. The BIOINCYTE bioactive scaffold is utilized within a controlled environment and sustains platelet growth factor releases over a course of days.
Platelet Rich Fibrin Matrices demonstrate many advantages over traditional PRP. PRFM has the ability to retain more growth factors than you would typically see in normal PRP devices. PRFM provides a softer more insulated approach to platelet separation, which allows for less trauma to individual blood cells. The PRFM scaffold matrix allows users to deliver more beneficial cells to the treatment site. Platelets and growth factors remain viable in a bio-active scaffolding environment with a controlled time release lasting for days, as opposed to traditional PRP which generally has a controlled time release only lasting for minutes to hours.
“The BIOINCYTE Platelet Rich Fibrin Matrix System creates a unique scaffold to localize platelets to the site of injection which allows for sustained growth factor release, migration of stem cells and reservoir for regenerative signaling,” said Salvatore Leo, Chief Executive Officer of Royal Biologics.
Source: Royal Biologics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
